tgAAC 09

Drug Profile

tgAAC 09

Alternative Names: Gag-PR-RT AAV HIV vaccine; HIV vaccine - Targeted Genetics; tgAAC-09

Latest Information Update: 11 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Targeted Genetics
  • Developer Columbus Childrens Hospital; International AIDS Vaccine Initiative; Targeted Genetics Corporation; The Childrens Hospital of Philadelphia
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 12 Mar 2007 Data presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI-2007) added to the adverse events and Viral Infections immunogenicity sections
  • 12 Mar 2007 Phase-I clinical trials in HIV infections prevention in European Union (IM)
  • 28 Jun 2006 Targeted Genetics and the International Aids Vaccine Initiative have extended their collaboration for the development of HIV/AIDS vaccines in the developing world
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top